Climate Change Data

Environmental Metrics

Climate Goals & Targets

Environmental Challenges

• Limited operating history and no revenue from product sales.
• Net losses in every year since inception.
• Dependence on the success of Iomab-B and the SIERRA trial.
• Lack of commercial sales and marketing capabilities.
• Potential adverse effects from the COVID-19 pandemic on clinical trials and operations.
• Potential disagreements with FDA or comparable foreign regulatory authorities regarding regulatory plans.
• Difficulties enrolling patients in clinical trials.
• Reliance on third parties for clinical trials and manufacturing.
• Potential for undesirable side effects or other properties that could halt clinical development or limit commercial potential.
• Intellectual property related to licensed antibodies may have expired or may expire.
• Potential insufficient supply of isotopes to support clinical development or commercial scale.
• Competition from other biotechnology and pharmaceutical companies.
• Potential conflicts with partners.
• Potential for limited or unavailable coverage and reimbursement in certain market segments.
• Potential claims of wrongful use or disclosure of confidential information.
• Managing growth as operations expand may strain resources.
• Potential for acquisitions to disrupt business or dilute stockholder ownership.
• Common stock is considered a penny stock.
• Potential delisting from NYSE American.
• Price volatility of common stock.
• No dividends paid on common stock.
• Certificate of Incorporation and Bylaws provisions make acquisitions more difficult.
• Compliance with reporting requirements of federal securities laws can be expensive.
• Ability to utilize net operating loss carryforwards may be limited.
• Failure to establish and maintain adequate finance infrastructure and accounting systems and controls.

Mitigation Strategies

• Issued and sold 210.8 million shares of common stock in April 2020, raising $31.6 million in gross proceeds.
• Implemented remote working in response to COVID-19.
• Continuously evaluating I-131 manufacturers and suppliers.
• Evaluating alternatives and second/third sources of supply or manufacturing for core suppliers and manufacturing partners.
• Developing a clinical trial designed to test the safety and efficacy of Iomab-B.
• Working with the FDA to develop a regulatory pathway for Actimab-MDS trial.
• Seeking to effect a reverse stock split to increase the price of common stock.

Supply Chain Management

Climate-Related Risks & Opportunities